PCV13-TT

Pneumococcal conjugate vaccine 13-valent with tetanus toxoid carrier protein · Walvax Biotechnology Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PCV13-TT, covering 2024-07-03 to 2024-07-03. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13 [Phase 3]

See pricing